6QC Stock Overview
Researches, develops, produces, and sells ethical drugs, active pharmaceutical ingredients, and intermediates in Japan.
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
Towa Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥16.70 |
| 52 Week High | JP¥19.70 |
| 52 Week Low | JP¥10.90 |
| Beta | 0.038 |
| 1 Month Change | 1.83% |
| 3 Month Change | -1.76% |
| 1 Year Change | 39.17% |
| 3 Year Change | -6.51% |
| 5 Year Change | n/a |
| Change since IPO | 1.13% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6QC | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 5.0% | 0.01% | 0.1% |
| 1Y | 39.2% | -19.6% | 9.1% |
Return vs Industry: 6QC exceeded the German Pharmaceuticals industry which returned -19.6% over the past year.
Return vs Market: 6QC exceeded the German Market which returned 9.1% over the past year.
Price Volatility
| 6QC volatility | |
|---|---|
| 6QC Average Weekly Movement | 4.0% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.5% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 6QC has not had significant price volatility in the past 3 months.
Volatility Over Time: 6QC's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1951 | 4,298 | Itsuro Yoshida | www.towayakuhin.co.jp |
Towa Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells ethical drugs, active pharmaceutical ingredients, and intermediates in Japan. The company provides its products in the therapeutic areas of digestive system, nervous system, and allergic diseases, as well as vitamins, antibiotics, and oncology products. It also offers IT service related to healthcare; and disease risk testing services.
Towa Pharmaceutical Co., Ltd. Fundamentals Summary
| 6QC fundamental statistics | |
|---|---|
| Market cap | €828.92m |
| Earnings (TTM) | €94.77m |
| Revenue (TTM) | €1.34b |
8.7x
P/E Ratio0.6x
P/S RatioIs 6QC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6QC income statement (TTM) | |
|---|---|
| Revenue | JP¥227.93b |
| Cost of Revenue | JP¥146.55b |
| Gross Profit | JP¥81.38b |
| Other Expenses | JP¥65.21b |
| Earnings | JP¥16.17b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 328.58 |
| Gross Margin | 35.70% |
| Net Profit Margin | 7.10% |
| Debt/Equity Ratio | 132.3% |
How did 6QC perform over the long term?
See historical performance and comparison